NovoCure (NASDAQ:NVCR) Stock Rating Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of NovoCure (NASDAQ:NVCR) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a research note on Friday, July 24th. Wells Fargo & Company cut their price objective on shares of NovoCure from $20.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Friday. HC Wainwright set a $32.00 target price on NovoCure in a research note on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of NovoCure in a research note on Thursday, August 27th. Finally, JPMorgan Chase & Co. initiated coverage on NovoCure in a research report on Monday, July 13th. They issued a “neutral” rating and a $17.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $20.80.

NovoCure Price Performance

Shares of NVCR opened at $13.15 on Friday. The firm has a market cap of $1.53 billion, a PE ratio of -12.41 and a beta of 0.99. NovoCure has a 52-week low of $9.82 and a 52-week high of $21.45. The business’s 50 day moving average price is $15.79 and its two-hundred day moving average price is $14.79. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.14. The company had revenue of $193.40 million during the quarter, compared to the consensus estimate of $182.28 million. NovoCure had a negative net margin of 16.78% and a negative return on equity of 36.18%. The company’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.33) EPS. On average, equities analysts anticipate that NovoCure will post -1.20 EPS for the current year.

Institutional Investors Weigh In On NovoCure

A number of institutional investors and hedge funds have recently bought and sold shares of NVCR. Quantinno Capital Management LP lifted its position in shares of NovoCure by 23.7% during the 1st quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock worth $27,112,000 after buying an additional 477,128 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of NovoCure by 11.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,551,554 shares of the medical equipment provider’s stock worth $16,912,000 after buying an additional 163,800 shares during the last quarter. Dimensional Fund Advisors LP grew its position in NovoCure by 27.6% during the first quarter. Dimensional Fund Advisors LP now owns 960,056 shares of the medical equipment provider’s stock valued at $10,462,000 after buying an additional 207,913 shares during the period. Allianz Asset Management GmbH bought a new position in NovoCure during the second quarter valued at about $2,248,000. Finally, California State Teachers Retirement System grew its position in NovoCure by 43.6% during the first quarter. California State Teachers Retirement System now owns 142,561 shares of the medical equipment provider’s stock valued at $1,554,000 after buying an additional 43,257 shares during the period. 84.61% of the stock is owned by hedge funds and other institutional investors.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. Its adjusted loss of $0.09 per share was substantially narrower than the expected $0.23 loss and the year-ago loss of $0.33. NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat
• Positive Sentiment: Management raised its 2026 guidance, reinforcing expectations for continued revenue growth and improved financial performance. The earnings call also provided additional detail on the company’s commercial and clinical strategy. NovoCure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
• Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 for pancreatic cancer. The partnership could expand the company’s pipeline and future indications. NovoCure and Verastem Collaboration
• Neutral Sentiment: Despite the earnings beat, NovoCure remains unprofitable, with a negative net margin and return on equity. Investors therefore remain focused on whether higher revenue and raised guidance can translate into sustainable profitability. NovoCure Third-Quarter Results
• Negative Sentiment: NovoCure’s CEO said adoption of the Optune Pax system was slowed by competition from Revolution Medicines’ daraxonrasib. Wedbush characterized the issue as a disruption rather than direct competition, but the slower adoption raises concerns about near-term commercial momentum. Optune Pax Adoption Commentary
• Negative Sentiment: Wells Fargo lowered its price target for NVCR from $20 to $15 and maintained an “equal weight” rating. Although the new target implies upside, the sharp reduction signals reduced confidence in the stock’s near-term risk-reward profile. Wells Fargo NovoCure Rating

About NovoCure

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.